Mounjaro CDSCO alert flags six KwikPen batches across every strength in India

India's drug regulator has listed six batches of Eli Lilly's Mounjaro KwikPen as not of standard quality. The Mounjaro CDSCO alert, part of the Central Drugs Standard Control Organisation's September 2026 list, covers every strength of the tirzepatide pen sold in India, according to a report by The South First. Each entry names the assay test, and two batches also carry sterility findings. The alert gives no test values, and the report did not carry a response from Lilly. Here is what the listing shows, what it leaves out and what to watch next.

What the September alert says about Mounjaro KwikPen batches

The Central Drugs Standard Control Organisation (CDSCO) issues a monthly drug quality alert that lists medicine samples failing tests at government laboratories. Its September 2026 edition names six Mounjaro KwikPen batches, one for each of the six strengths Lilly sells in India, according to a report on the September list. All six entries cite the assay test, which checks how much active ingredient a product holds against its specification. The lowest strength batch also failed sterility testing. The second strength batch failed sterility and a test for related substances and impurities. The entry for the fourth strength is worded differently and does not plainly state that the sample failed. The report lists Eli Lilly Italy SPA as manufacturer and Lilly's Indian unit, Eli Lilly and Company (India) Pvt Ltd, as importer.

Mounjaro contains tirzepatide, a peptide that acts on both GIP and GLP-1 receptors, which help regulate blood sugar and appetite. Lilly launched it in India in March 2025 for type 2 diabetes and for weight management in eligible adults. The listing names an Italian manufacturer and an Indian importer, so every pen in question reached Indian patients through import. Yet the Mounjaro CDSCO alert does not say which laboratory tested the pens, where in the supply chain the samples were drawn, or when they were collected. Those missing details would help show whether any problem began at the plant, during shipping and storage, or later on a pharmacy shelf. The table below sets out each entry as the report describes it.

Why assay and sterility results matter for tirzepatide in India

Each test answers a different question. An assay result shows whether the amount of drug in the pen matches what the label claims. A sterility test checks for microbial contamination, a basic requirement for any injectable medicine. A related substances test looks for impurities and other chemical components that should be absent or held below set limits. Failing an assay can mean too little or too much drug, but the September alert gives no figures, so readers cannot tell how far any sample strayed from the standard. For tirzepatide in India, that gap matters, because a small shortfall and a large one would point to very different causes and very different levels of concern for prescribers.

Failing an assay can mean too little or too much drug, but the September alert gives no figures, so readers cannot tell how far any sample strayed from the standard.

On paper, the sterility findings on two batches are the most serious part of the listing, since contamination risk is the main reason injectables face strict testing. Still, the alert reports results on tested samples, and the report does not say whether other units from the same batches were checked. Peptide pens are demanding products to make: our story on Dr Reddy's semaglutide restart showed how one impurity found after a scale up halted a generic pen line for months. Nothing in the alert says Lilly's Italian plant has a similar problem. People in India who use Mounjaro and have questions about a specific pen should speak to their doctor or pharmacist rather than change treatment on their own. This story is not medical advice.

How not of standard quality listings work in India

In India, a drug sample listed as not of standard quality, or NSQ, has failed one or more of the tests set for it. The alert keeps a separate section for spurious drugs, the term used for fake or falsely presented products. The September 2026 list holds 330 NSQ entries and a single entry in the spurious drug section, according to The South First. The Mounjaro batches sit in the NSQ section. The one spurious drug entry is an amoxycillin and clavulanate tablet, Ricmox-CV 625 from Alexa Pharmaceuticals, which failed identification for clavulanic acid and assay for amoxycillin, and which a laboratory declared spurious. On the alert's own terms, then, the Mounjaro pens are recorded as products that failed tests, not as counterfeits.

The September list is broad. It also covers diabetes tablets containing glimepiride, sitagliptin or metformin, several telmisartan blood pressure products, thyroid tablets, paracetamol, antibiotics, intravenous fluids and cough syrups, the report says. Ringer lactate, normal saline and a pantoprazole injection failed sterility, and Baxter's Dianeal dialysis solutions failed a bacterial endotoxin test. Five cosmetics exceeded the mercury limit of 1 part per million under the Cosmetics Rules, 2020. Against that crowded list, the Mounjaro CDSCO alert stands out because it concerns a new imported peptide from a global drugmaker rather than a low cost local generic. Fake tirzepatide is a live problem elsewhere, as the MHRA counterfeit pens haul in Birmingham showed, but nothing in this alert points to fakes.

What Lilly and CDSCO have not said yet

Several basic facts are still missing. The South First report did not include a statement from Lilly, and it does not say whether any of the six batches has been recalled or held back from sale. The report gives no manufacturing or expiry dates and no test values. It also does not name the laboratory that tested the Mounjaro samples, although other entries in the same alert name state and central laboratories in places such as Vijayawada, Lucknow and Kolkata. Without those details, it is not possible to say whether the findings point to a manufacturing fault, a storage or transport issue, or a testing question that the company may dispute. For now the listing is a regulatory flag, not a finding of harm to patients.

The next steps are clear questions rather than answers. Watch for a statement from Eli Lilly India on whether it accepts the results or plans to contest them, and for any recall notice from CDSCO or state drug controllers. Later monthly alerts will show whether further Mounjaro samples pass or fail. The finding also arrives as tirzepatide gains new uses in other Asian markets, such as the recent Mounjaro Korea approval that added heart risk reduction and paediatric type 2 diabetes to the label. Quality questions in one market do not change the clinical evidence behind the drug, but they do shape trust among doctors, pharmacists and patients who rely on a steady supply of tested, imported pens.

Conclusion

The Mounjaro CDSCO alert lists six imported KwikPen batches, one per strength, as not of standard quality, with assay entries on all six and sterility failures on two. It gives no test values or sample sources, and no company response was reported. Until Lilly or the regulator says more, the listing is a signal to follow rather than a verdict on the product. The next monthly alerts and any recall notice will show whether the problem stays limited to these samples.